Pharma cos now demanding return on digital investments but some still risk being left behind, says DiMe Society's Jennifer Goldsack

*Partnered content

Talking the talk alone is no longer enough for pharma companies where their digital strategies are concerned—now they need to walk the walk, too.

Cajoled by the pandemic and ongoing challenges with clinical trials, including studies’ low rates of technical success, protracted timelines, recruitment and retention failures, as well as ever-increasing pressures to find new revenue streams as patent cliffs draw near, drugmakers now want to see digital investments bearing fruit.